Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9UBR2
UPID:
CATZ_HUMAN
Alternative names:
Cathepsin P; Cathepsin X
Alternative UPACC:
Q9UBR2; B2RC40; O75331; Q9UQV5; Q9UQV6
Background:
Cathepsin Z, also known as Cathepsin P and Cathepsin X, is a protease enzyme exhibiting both carboxy-monopeptidase and carboxy-dipeptidase activities. Its ability to produce kinin potentiating peptides suggests a significant role in physiological processes.
Therapeutic significance:
Understanding the role of Cathepsin Z could open doors to potential therapeutic strategies. Its enzymatic functions hint at its importance in biological systems, making it a target for drug discovery efforts.